Categories
Science

Chinese spacecraft enters Mars’ orbit, joining Arab ship

In this undated photo released by the China National Space Administration, a view of the planet Mars is captured by China’s Tianwen-1 Mars probe from a distance of 2.2 million kilometers (1.37 million miles). A Chinese spacecraft appears poised to enter orbit around Mars on Wednesday, Feb. 10, 2021, one day after an orbiter from the United Arab Emirates did so, and about a week ahead of an American attempt to put down another spacecraft on the surface of the red planet. (CNSA/Xinhua via AP)

 

BEIJING (AP) — A Chinese spacecraft went into orbit around Mars on Wednesday on an expedition to land a rover on the surface and scout for signs of ancient life, authorities announced in a landmark step in the country’s most ambitious deep-space mission yet.

The arrival of Tianwen-1 after a journey of seven months and nearly 300 million miles (475 million kilometers) is part of an unusual burst of activity at Mars: A spacecraft from the United Arab Emirates swung into orbit around the red planet on Tuesday, and a U.S. rover is set to arrive next week.

China’s space agency said the five-ton combination orbiter and rover fired its engine to reduce its speed, allowing it to be captured by Mars’ gravity.

“Entering orbit has been successful … making it our country’s first artificial Mars satellite,” the agency announced.

The mission is bold even for a space program that has racked up a steady stream of achievements and brought prestige to China’s ruling Communist Party.

If all goes as planned, the rover will separate from the spacecraft in a few months and touch down safely on Mars, making China only the second nation to pull off such a feat. The rover, a solar-powered vehicle about the size of a golf cart, will collect data on underground water and look for evidence that the planet may have once harbored microscopic life.

Tianwen, the title of an ancient poem, means “Quest for Heavenly Truth.”

Landing a spacecraft on Mars is notoriously difficult. Smashed Russian and European spacecraft litter the landscape along with a failed U.S. lander. About a dozen orbiters missed the mark. In 2011, a Mars-bound Chinese orbiter that was part of a Russian mission didn’t make it out of Earth orbit.

Only the U.S. has successfully touched down on Mars — eight times, beginning with two Viking missions in the 1970s. An American lander and rover are in operation today.

China’s attempt will involve a parachute, rocket firings and airbags. Its proposed landing site is a vast, rock-strewn plain called Utopia Planitia, where the U.S. Viking 2 lander touched down in 1976.

Before the arrival this week of the Chinese spacecraft and the UAE’s orbiter, six other spacecraft were already operating around Mars: three U.S., two European and one Indian.

All three of the latest missions were launched in July to take advantage of the close alignment between Earth and Mars that happens only once every two years.

A NASA rover called Perseverance is aiming for a Feb. 18 landing. It, too, will search for signs of ancient microscopic life, collecting rocks that will be returned to Earth in about a decade.

China’s secretive, military-linked space program has racked up a series of achievements. In December, it brought moon rocks back to Earth for the first time since the 1970s. China was also the first country to land a spacecraft on the little-explored far side of the moon in 2019.

China is also building a permanent space station and planning a crewed lunar mission and a possible permanent research base on the moon, though no dates have yet been proposed.

While most contacts with NASA are blocked by Congress and China is not a participant in the International Space Station, it has increasingly cooperated with the European Space Agency and countries such as Argentina, France and Austria. Early on, China cooperated with the Soviet Union and then Russia.

 

— Associated Press

Categories
Healthcare

LianBio announces $310 million crossover financing

Supported by a strong U.S. and Chinese investor syndicate including Perceptive Advisors, RA Capital, Venrock Healthcare Capital Partners and CMG-SDIC Capital

Proceeds will fund advancement of the Company’s global innovation mining platform and diversified portfolio of product candidates

SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a Chinese company focused on bringing paradigm-shifting medicines to patients in China and major Asian markets, today announced it has raised $310 million in an oversubscribed crossover financing, following its founding and initial financing provided by Perceptive Advisors.

The financing was co-led by U.S. investors RA Capital and Venrock Healthcare Capital Partners and Chinese investor CMG-SDIC Capital. Other leading specialist investors in the round included: funds and accounts managed by BlackRock, Casdin Capital, Farallon, Logos Capital, Perceptive Advisors, Pfizer Inc., Sphera Healthcare, funds and accounts advised by T. Rowe Price Associates, Inc., Tybourne Capital Management, Vida Ventures, Viking Global Investors and Wellington Management.

We are excited to partner with this world class group of investors who share our vision of accelerating broad access to transformative medicines for patients in China and other major Asian markets. Building on the success and momentum of the Company’s recent launch, this financing provides additional support for LianBio’s efforts to contribute to China’s dynamic life sciences landscape by addressing significant unmet medical needs in the region,” said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman of LianBio. “We are proud of the management team who is rapidly realizing our vision and has proven that partnership, passion and commitment can help spur the delivery of innovative therapies to the fast-growing biopharma marketplace in China.”

With the Company’s global innovation mining platform validated by an impressive syndicate of investors, LianBio is poised to advance its business model in China and major Asian markets.

Jefferies LLC acted as exclusive placement agent for the financing.

About LianBio

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics. For more information, please visit lianbio.com.

Contacts

Investor Contact:
Thomas Hoffmann

Solebury Trout

646-378-2931

thoffmann@soleburytrout.com

Media Contact:
Hannah Gendel

Solebury Trout

646-378-2943

hgendel@soleburytrout.com